IP Library Granted Patent US 10,829,758
Granted Patent B2
US 10,829,758 · App. 15/570,947 · Granted Nov 10, 2020

Automatable method for nucleic acid isolation

Inventors: Geert Meersseman (Brussels, BE); Klaas DeCanniere (Ottenburg, BE)
Assignee: BIOCARTIS, NV
C12N15/1006C12Q1/686
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,829,758
App. No.
15/570,947
Granted
Nov 10, 2020
Kind
B2
Abstract

The present invention relates to a highly automatable method for isolation and/or purification of nucleic acids from a biological sample, which is particularly suitable for nucleic acids-shorter than 250 bp and can be performed without a proteolytic pre-digestion step in an automated system, preferably a cartridge-based system. In a further aspect, the present invention also provides automated nucleic acid detection methods based on said isolation and/or purification method, as well as buffers and kits to be used in performing said methods.

Claims (22)

1. A method for isolating and/or purifying nucleic acids from a nucleic acid-containing starting material, the method comprising: step (a) binding the nucleic acids to a nucleic acid binding support material by contacting the nucleic acid-containing starting material with the nucleic acid binding support in the presence of at least one chaotropic compound and at least one alcohol, wherein:

(i) the alcohol is an alcohol having 4 or 5 carbon atoms and is present at a concentration between about 17% (v/v) and about 50% (v/v), and in that

(ii) the at least one chaotropic compound is present at a concentration between about 1.5 M and about 4.5 M.

2. The method of claim 1 further comprising: step (b) eluting the bound nucleic acids from the nucleic acid binding support material with an elution buffer.

3. The method according to claim 1 , wherein no protease is added to step (a) or no incubation with a protease is performed directly before subjecting the nucleic acid-containing starting material to step (a).

4. The method according to claim 1 , wherein the alcohol having 4 or 5 carbon atoms is a monohydroxy alcohol.

5. The method according to claim 4 , wherein the monohydroxy alcohol is selected from the group consisting of n-butanol, sec-butanol, isobutanol, tert-butanol, 1-pentanol, 2-pentanol, 3-pentanol, 2-methyl 1-butanol, 3-methyl 1-butanol, 2,2-dimethyl 1-propanol, 2- methyl 2-butanol, 3-methyl 2-butanol, or a mixture thereof.

6. The method according to claim 4 , wherein the monohydroxy alcohol is selected from the group consisting of n-butanol, 1-pentanol, sec-butanol, isobutanol, tert-butanol, or a mixture thereof.

7. The method according to claim 1 , wherein the alcohol having 4 or 5 carbon atoms is present in step (a) at a concentration between about 20% (v/v) and about 50% (v/v).

8. The method according to claim 1 , wherein the alcohol having 4 or 5 carbon atoms is present in step (a) at a concentration between about 35% (v/v) and about 40% (v/v).

9. The method according to claim 1 , wherein the at least one chaotropic compound is selected from thiocyanates, isocyanates, perchlorates, hydrochlorides, or mixtures thereof.

10. The method according to claim 1 , wherein the at least one chaotropic compound is guanidinium thiocyanate.

11. The method according to claim 1 , wherein the at least one chaotropic compound is present in step (a) at a concentration between about 2 M and about 4.5 M.

12. The method according to claim 1 , wherein the at least one chaotropic compound is present in step (a) at a concentration between about 3 M and about 3.5 M.

13. The method according to claim 1 , wherein the nucleic acid-containing starting material is a liquid biological sample selected from the group consisting of whole blood, serum, plasma, cerebrospinal fluid (CSF), and urine.

14. The method according to claim 1 , wherein said method is performed on an automated system on a removable cartridge.

15. An automated diagnostic method for detecting target nucleic acids, the method comprising the steps of:

(a) providing a nucleic acid-containing starting material into an automated system;

(b) isolating and/or purifying nucleic acids in said automated system, according to the method of claim 1 ;

(c) performing amplification in said automated system of target nucleic acids isolated and/or purified in step (b); and

(d) detecting the target nucleic acids amplified in step (c).

16. The automated diagnostic method according to claim 15 , wherein at least the steps (b) and (c) are performed on a cartridge.

Assignments (5)
SECURITY INTEREST Recorded Oct 31, 2023
From: BIOCARTIS NV
To: GLAS TRUST CORPORATION LIMITED
Reel/Frame 065411/0175 →
SECURITY INTEREST Recorded Nov 4, 2022
From: BIOCARTIS NV
To: GLAS TRUST CORPORATION LIMITED
Reel/Frame 061657/0976 →
SECURITY INTEREST Recorded Oct 28, 2022
From: BIOCARTIS NV
To: GLAS TRUST CORPORATION LIMITED
Reel/Frame 061583/0397 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2018
From: NAUWELAERS, DAVID; KENENS, HANNAH
To: BIOCARTIS, NV
Reel/Frame 046236/0946 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2018
From: MEERSSEMAN, GEERT; DECANNIERE, KLAAS
To: BIOCARTIS, NV
Reel/Frame 046237/0146 →
Priority Claims (1)
EP 15171261 · Jun 9, 2015 · regional
Continuity (1)
Related Publication 20180291367A1 · Oct 11, 2018